Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - felint calicivirus (fcv), stamme f9 (levende, svækket), felint herpesvirus type 1 (fhv), stamme g2620a (levende, svækket) - lyofilisat og solvens til injektionsvæske, suspension

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

elanco animal health a/s - felint calicivirus (fcv), stamme f9 (levende, svækket), felint panleukopenivirus (fpv), stamme snow leopard (levende, svækket), felint rhinotracheitisvirus (fvr), stamme fvrm (levende, svækket) - pulver og solvens til injektionsvæske, suspension

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

zoetis animal health aps - felin panleukopenivirus, stamme cu4 (inaktiveret), felint calicivirus (fcv), stamme 255 (inaktiveret), felint chlamydia psittaci, stamme cello (inaktiveret), felint rhinotracheitisvirus, stamme 605 (inaktiveret) - injektionsvæske, suspension

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - felint calicivirus (fcv), stamme f9 (levende, svækket), felint panleukopenivirus (fplv), stamme mw-1 (levende, svækket), felint rhinotracheitisvirus (fvr), stamme fvrm (levende, svækket) - lyofilisat og solvens til injektionsvæske, suspension

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svin - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - felin leukæmi virus rekombinant canarypox virus (vcp97) - immunologicals for felidae, - katte - aktiv immunisering af katte, der er 8 uger gamle eller ældre mod feline leukæmi til forebyggelse af vedvarende viraemia og kliniske tegn på den relaterede sygdom. immunitetsbegyndelsen er påvist 2 uger efter primær vaccination. varigheden af ​​immunitet er et år efter den sidste vaccination.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - immunologicals for dyr af hareordenen - kaniner - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologiske - katte - aktiv immunisering af katte 12 uger gamle og ældre for at forhindre dødelighed på grund af rabiesinfektion. immunitetens begyndelse: 4 uger efter det primære vaccinationsforløb. immunitetens varighed efter primær vaccination: 1 år. immunitetens varighed efter revaccination: 3 år.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - calciumfolinat - injektions-/infusionsvæske, opløsning - 10 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kylling - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.